Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 84

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 84
---
4. With respect to the royalty-bearing
grants we are committed to pay royalties at a rate between 3% and 4.5% on sales proceeds from our products that were developed under
the IIA, programs up to the total amount of grants received, linked to the U.S. dollar and bearing interest at an annual rate of the
Term Secured Overnight Financing Rate, or SOFR, applicable to U.S. dollar deposits. Due to the accrual of interest, the total amount
of the grants that will be repaid through royalties will increase until repayments begin. We are further required to comply with the
requirements of the Israeli Encouragement of Industrial Research, Development and Technological Innovation Law, 5744-1984, as amended,
and related regulations, or the Research Law, with respect to those past grants. When a company develops know-how, technology or products
using IIA grants, the terms of these grants and the Research Law restrict the transfer or license of such know-how, and the transfer
of manufacturing or manufacturing rights of such products, technologies or know-how outside of Israel, without the prior approval of
the IIA. Therefore, the discretionary approval of an IIA committee would be required for any transfer or license to third parties inside
or outside of Israel of know-how or for the transfer outside of Israel of manufacturing or manufacturing rights related to those aspects
of such technologies. We may not receive those approvals. Furthermore, the IIA may impose certain conditions on any arrangement under
which it permits us to transfer technology or development.

The transfer or license of
IIA-supported technology or know-how outside of Israel and the transfer of manufacturing of IIA-supported products, technology or know-how
outside of Israel may involve the payment of significant amounts, depending upon the value of the transferred or licensed technology
or know-how, our research and development expenses, the amount of IIA support, the time of completion of the IIA-supported research project
and other factors. These restrictions and requirements for payment may impair our ability to sell, license or otherwise transfer our
technology assets outside of Israel or to outsource or transfer development or manufacturing activities with respect to any product or
technology outside of Israel. Furthermore, the consideration available to our shareholders in a transaction involving the transfer outside
of Israel of technology or know-how developed with IIA funding (such as a merger or similar transaction) may be reduced by any amounts
that we are required to pay to the IIA. The terms and